Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-01. Numbers and descriptions here follow the published literature rather than marketing material.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
, especially noticeable as temperatures exceed 30 °C. The temperature dependence of the electrical conductivity of fully deionized water without CO2 saturation is comparably low in relation to these data.
The most recent model, the Dexcom G7, features a redesigned sensor and updated algorithm, yielding a MARD of 8.2% in adults and 8.1% in children. The newest iteration of the Dexcom CGM, the Dexcom G7 15-Day CGM, has an even lower MARD of 8% in adult users.
Immune response – Nuclear actin polymerizes upon T-cell receptor stimulation and is required for cytokine expression and antibody production in vivo. DNA repair – Nuclear actin mediates the repair of DNA double-strand breaks. In the cell nucleus, a filamentous polymer of actin (F-actin) acts both in the DNA repair pathway of non homologous end joining and in the pathway of homologous recombinational repair. Due to its ability to undergo conformational changes and interaction with many proteins, actin acts as a regulator of formation and activity of protein complexes such as transcriptional complex.
Tweezing (hairs are tweezed, or pulled out, with tweezers or with fingers) Waxing (a hot or cold layer is applied and then removed with porous strips) Sugaring (hair is removed by applying a sticky paste to the skin in the direction of hair growth and then peeling off with a porous strip) Threading (also called fatlah or khite in Arabic, or band in Persian) in which a twisted thread catches hairs as it is rolled across the skin Epilators (mechanical devices that rapidly grasp hairs and pull them out). Drugs that directly attack hair growth or inhibit the development of new hair cells. Hair growth will become less and less until it finally stops; normal depilation/epilation will be performed until that time. Hair growth will return to normal if use of product is discontinued. Products include the following: The pharmaceutical drug eflornithine hydrochloride (with the trade names Vaniqa and Follinil) inhibits the enzyme ornithine decarboxylase, preventing new hair cells from producing putrescine for stabilizing their DNA. Antiandrogens, including spironolactone, cyproterone acetate, flutamide, bicalutamide, and finasteride, can be used to reduce or eliminate unwanted body hair, such as in the treatment of hirsutism. Although effective for reducing body hair, antiandrogens have little effect on facial hair. However, slight effectiveness may be observed, such as some reduction in density/coverage and slower growth. Antiandrogens will also prevent further development of facial hair, despite only minimally affecting that which is already there.
== Mechanisms == Chronic elevation of blood glucose level leads to damage of blood vessels called angiopathy. The endothelial cells lining the blood vessels take in more glucose than normal, since they do not depend on insulin. They then form more surface glycoproteins than normal, and cause the basement membrane to grow thicker and weaker. The resulting problems are grouped under "microvascular disease" due to damage to small blood vessels and "macrovascular disease" due to damage to the arteries. Studies show that DM1 and DM2 cause a change in balancing of metabolites such as carbohydrates, blood coagulation factors, and lipids, and subsequently bring about complications like microvascular and cardiovascular complications. The role of metalloproteases and inhibitors in diabetic renal disease is unclear. Numerous researches have found inconsistent results about the role of vitamins in diabetic risk and complications.
Sources: en.wikipedia.org
Some stegosaurs such as Kentrosaurus do not have a distinct "thagomizer" consisting of two pairs of spikes, as in these species there is not clear differentiation between the last two pairs on the tail and the other tail osteoderms, which are also spike-like, unlike the broad plate-like osteoderms on the back of Stegosaurus. There has been debate about whether the thagomizer was used simply for display, as posited by Gilmore in 1914, or used as a defensive weapon. Robert Bakker noted that it is likely that the stegosaur tail was much more flexible than those of other ornithischian dinosaurs because it lacked ossified tendons, thus lending credence to the idea of the thagomizer being a weapon. He also observed that Stegosaurus could have maneuvered its rear easily by keeping its large hindlimbs stationary and pushing off with its very powerfully muscled but short forelimbs, allowing it to swivel deftly to deal with attack. In 2010, analysis of a digitized model of Kentrosaurus aethiopicus showed that the tail could bring the thagomizer around to the sides of the dinosaur, possibly striking an attacker beside it.
Most classical force fields implicitly include the effect of polarizability, e.g., by scaling up the partial charges obtained from quantum chemical calculations. These partial charges are stationary with respect to the mass of the atom. But molecular dynamics simulations can explicitly model polarizability with the introduction of induced dipoles through different methods, such as Drude particles or fluctuating charges. This allows for a dynamic redistribution of charge between atoms which responds to the local chemical environment. For many years, polarizable MD simulations have been touted as the next generation. For homogenous liquids such as water, increased accuracy has been achieved through the inclusion of polarizability. Some promising results have also been achieved for proteins. However, it is still uncertain how to best approximate polarizability in a simulation. The point becomes more important when a particle experiences different environments during its simulation trajectory, e.g. translocation of a drug through a cell membrane.
=== La–Li === Irving Langmuir (1881–1957), American chemist, physicist, 1932 Nobel Prize in Chemistry for work in surface chemistry Auguste Laurent (1807–1853), French chemist who discovered trichloroethylene, anthracene, phthalic acid, and carbolic acid Paul Lauterbur (1929–2007), American chemist, Nobel Prize in Physiology or Medicine (2003) work which that the development of magnetic resonance imaging possible Antoine Lavoisier (1743–1794), French chemist who recognized oxygen and hydrogen as elements Nicolas Leblanc (1742–1806), French chemist and surgeon who discovered how to manufacture soda ash from common salt Henri Louis Le Chatelier (1850–1936), French chemist known for Le Chatelier's principle, which allows prediction of the effect of a changing condition on a system in chemical equilibrium Yuan T. Lee (born 1936), Taiwanese chemist, 1986 Nobel Prize in Chemistry for contributions to the development of reaction dynamics Valery Legasov (1936–1988), Soviet inorganic chemist known for his position as head of the Chernobyl Commission for the Chernobyl Disaster Jean-Marie Lehn (born 1939), French chemist, 1987 Nobel Prize in Chemistry for the synthesis of cryptands Marko Leko (1853–1932), Serbian chemist known for work on the nature of ammonium chloride Luis Federico Leloir (1906–1987), Argentine biochemist and winner of the 1970 Nobel Prize in Chemistry Raymond Lemieux (1920–2000), Canadian organic chemist, Wolf Prize in Chemistry Gilbert Newton Lewis (1875–1946), American chemist and first Dean of the Berkeley College of Chemistry
== Epidemiology == Globally, the prevalence and incidence of pulmonary fibrosis has been studied in the United States, Norway, Czech Republic, Greece, United Kingdom, Finland, and Turkey, with only two studies in Japan and Taiwan. But most of these studies were of people already diagnosed with pulmonary fibrosis, which lowers the diagnosis sensitivity, so that the prevalence and incidence has ranged from 0.7 per 100,000 in Taiwan to 63.0 per 100,000 in the U.S., and the published incidence has ranged from 0.6 per 100,000 person years to 17.4 per 100,000 person years. The mean age of all pulmonary fibrosis patients is between 65 and 70 years, making age a criterion of its own. Aging respiratory systems are much more vulnerable to fibrosis and stem cell depletion.
Sources: en.wikipedia.org
== Structure == Although no crystallographic x-ray diffraction analyses have been published that depict the entire structure of ADAM10, one domain has been studied using this technique. The disintegrin and cysteine-rich domain (shown to the right) plays an essential role in regulation of protease activity in vivo. Recent experimental evidence suggests that this region, which is distinct from the active site, may be responsible for substrate specificity of the enzyme. It is proposed that this domain binds to particular regions of the enzyme's substrate, allowing peptide bond hydrolysis to occur in well defined locations on certain substrate proteins. The proposed active site of ADAM10 has been identified by sequence analysis, and is identical to enzymes in the Snake Venom metalloprotein domain family. The consensus sequence for catalytically active ADAM proteins is HEXGHNLGXXHD. Structural analysis of ADAM17, which has the same active site sequence as ADAM10, suggests that the three histidines in this sequence bind a Zn2+ atom, and that the glutamate is the catalytic residue.
In 2002, the Nobel Prize in Chemistry was awarded to John Bennett Fenn for the development of electrospray ionization (ESI) and Koichi Tanaka for the development of soft laser desorption and their application to the ionization of biological macromolecules, especially proteins.
The historian Ahmed Beydoun describes the efforts by 20th-century Maronite authors to emphasize the Maronite role in the events as an attempt to prove the community's early presence in the Kisrawan. In this way, the Maronites' abandonment of the region in the aftermath of the campaigns could be described as a "forced exile" and the Maronite settlement of the Kisrawan in the 16th and 17th centuries as their "return". On the other hand, Beydoun views the narratives of the expeditions by modern Shia Lebanese historians, which emphasize Shia Muslims' defense of the mountains' autonomy from the Mamluks, as part of an effort to bolster Shia credentials as a core Lebanese community. Lebanese Sunni authors generally write of the campaigns from a pro-Mamluk stance, seeing in them the legitimate Muslim state's efforts to incorporate Mount Lebanon into the Islamic realm, while Druze authors write with a focus on the Druze community's consistent connection to Mount Lebanon and defense of its practical autonomy.
Official website Food and Drug Administration in the Federal Register Food and Drug Administration in the Code of Federal Regulations Strategic Plan (archived) Works by Food and Drug Administration at Open Library Online books by United States Food and Drug Administration at The Online Books Page Food and Drug Administration apportionments on OpenOMB
== External links == Vincent du Vigneaud on Nobelprize.org including the Nobel Lecture, December 12, 1955 A Trail of Sulfa Research: From Insulin to Oxytocin https://weill.cornell.edu/archives/pdf/personal_aids/DuVigneaud.pdf
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.